The Impact of Time Restricted Eating on Type 2 Diabetes
Key facts
- Who runs it
- Rockefeller University
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 2 people enrolled
- Started
- 29 May 2025
- Ended
- 4 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Meal timing
- Time restricted eating
- Usual feeding pattern.
- Record updated
- 20 January 2026
- Why it stopped
- clinical facility could no longer support study conduct; loss of funding, PI left the institution
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Age 18-75 able to give consent
- BMI >25 kg/m2
- Hemoglobin A1C ≥ 6.5%
- Willing to eat only the food provided
- Willing to follow the feeding schedule, including fasting for 16 hours/day for six days
- Usual sleep time is between 10 PM and 8 AM
- Fluent in the English language
Who cannot take part
- Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat)
- Current use of steroids (inhalers are permissible)
- Report history of Cirrhosis
- HIV positive
- Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.)
- Allergy to adhesive tape
- Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data
- Hemoglobin A1c >8%
- Currently pregnant
- Smoked tobacco within the last 3 months
- Skips breakfast
- Followed TRF or intermittent fasting in the last 2 weeks
- Shift or night worker
- Current use of insulin
- Current use of sulfonylureas
- Current use of glucagon-like peptide-1 (GLP-1) receptor agonists
- Unable to sync smartphone with Bluetooth for scale data
Where in United States
- The Rockefeller University HospitalNew York, United States
About the trial
What the trial wants to find out
Time-restricted feeding limits caloric intake to active daytime hours with fasting for 14 to 16 hours. It has shown great promise as a novel intervention for stabilizing blood glucose, reducing weight, and improving cardiovascular disease outcomes. However, this approach has not been tested on people with diabetes, a group that would benefit from improved blood glucose and weight loss.
Read full original descriptionShow less
The impact of Time-Restricted Eating on Type 2 Diabetes Study (EaT2D Study) is a randomized six-day weight stable crossover feeding study in the Day Patient/Outpatient unit of The Rockefeller Hospital investigating how the time of day that meals are eaten affects weight, blood sugar and blood pressure. The investigators will compare an early time-restricted eating intervention (80% of calories consumed before 2 pm) to a usual feeding pattern (50% of calories consumed after 4 pm) among 10 persons with type 2 diabetes to determine effects on blood sugar and small molecules found in the blood.
Studies have shown benefits of eating during active periods (mornings and early afternoon) for metabolic health (blood sugar, body weight) compared to eating during inactive periods (evening and bedtime). Eating earlier in the day may lead to reduced sugar stores, burning fat for energy, and decreased inflammation when compared to eating later in the day. The investigators will compare the effects of eating earlier during the day for six days versus later in the day for six days, on blood sugar, blood pressure, blood ketones, and other measures of metabolic health in diabetic participants. Studies in animals supports these benefits.
The 2 groups in the trial
- Time restricted eatingExisting treatment, for comparison
Selection of the order of the arms is randomized prior to active study participation. Caloric requirements and meal selection are done during screening and calculated to maintain weight neutrality. In Arm 1, participants are required to start breakfast at 8 AM, complete lunch by 2 PM (80% of total daily calories) and snack by 4 PM (20% of calories). They then fast from 4 PM till 8 AM the next day (16 hour fast). This is done for six days. The next day is for testing (2 hour oral glucose tolerance test, resting energy expenditure, research and clinical blood tests) prior to crossover to Arm 2.
Treatment: Meal timing and Time restricted eating
- Usual feeding pattern, with meals eaten ad libPlacebo, for comparison
Participants consume the same meals as in the other arm, but may eat ad lib without prolonged fasting. This is done for six days. Post-testing including 2 hour oral glucose tolerance test, resting energy expenditure, and research and clinical blood tests are done the following day.
Treatment: Usual feeding pattern.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Time Restricted Eating on Type 2 Diabetes Study
- Record updated
- 20 January 2026